Dr. Anne S. Tsao, MD of MD Anderson Cancer Center discusses about their study of LUME-MESO Trial for mesothelioma treatment. In this study, they use antiandrogenics in the front-line setting with the combination of Cisplatin, Pemetrexed and Nintedanib. This two-phase trial was presented at ASCO this year. Results showed an overwhelming superior progression-free survival (PFS) with the combination of Cisplatin, Pemetrexed and Nintedanib given for six cycles, followed by Nintedanib Maintenance Therapy. In the randomized Phase II of the trial, the demonstrated PFS had a median hazard ratio of around 0.57, which was statistically significant. Currently, there is an ongoing Phase III of the trial to determine whether LUME-Meso should move forward or not. Based on the data from the MAPS Trial from the IFCT two years ago, they suspected that the antiandrogenics with the combination of Cisplatin and Pemetrexed may be beneficial for patients with mesothelioma.